Trial Profile
Phase I, open-label study, to evaluate the potential effect of hepatic impairment on the pharmacokinetics and safety of a single dose of fasiglifam and its metabolite M-I.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2018
Price :
$35
*
At a glance
- Drugs Fasiglifam (Primary)
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- 07 Mar 2018 New trial record
- 27 Feb 2018 Results published in the Drugs in R and D